202 related articles for article (PubMed ID: 15883258)
1. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
2. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
[TBL] [Abstract][Full Text] [Related]
3. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
4. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
5. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression.
Holthoff VA; Beuthien-Baumann B; Kalbe E; Lüdecke S; Lenz O; Zündorf G; Spirling S; Schierz K; Winiecki P; Sorbi S; Herholz K
Biol Psychiatry; 2005 Feb; 57(4):412-21. PubMed ID: 15705358
[TBL] [Abstract][Full Text] [Related]
6. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Goekoop R; Scheltens P; Barkhof F; Rombouts SA
Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
[TBL] [Abstract][Full Text] [Related]
7. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
[TBL] [Abstract][Full Text] [Related]
8. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
Bokde AL; Karmann M; Teipel SJ; Born C; Lieb M; Reiser MF; Möller HJ; Hampel H
J Clin Psychopharmacol; 2009 Apr; 29(2):147-56. PubMed ID: 19512976
[TBL] [Abstract][Full Text] [Related]
9. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.
Kim YW; Kim DY; Shin JC; Park CI; Lee JD
Clin Neuropharmacol; 2009; 32(2):63-8. PubMed ID: 18978490
[TBL] [Abstract][Full Text] [Related]
10. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Penner J; Rupsingh R; Smith M; Wells JL; Borrie MJ; Bartha R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):104-10. PubMed ID: 19833161
[TBL] [Abstract][Full Text] [Related]
11. Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer's disease: a study using positron emission tomography with fluorodeoxyglucose-F18.
Zahn R; Juengling F; Bubrowski P; Jost E; Dykierek P; Talazko J; Huell M
Psychiatry Res; 2004 Dec; 132(2):159-72. PubMed ID: 15598550
[TBL] [Abstract][Full Text] [Related]
12. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.
Goekoop R; Rombouts SA; Jonker C; Hibbel A; Knol DL; Truyen L; Barkhof F; Scheltens P
Neuroimage; 2004 Dec; 23(4):1450-9. PubMed ID: 15589109
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
[TBL] [Abstract][Full Text] [Related]
15. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
16. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
18. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
19. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
Rockwood K; Fay S; Gorman M
Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
